Receptors, Thrombin
-
Subject Areas on Research
- A functional tethered ligand thrombin receptor is present on human hematopoietic progenitor cells.
- Alpha-adducin dissociates from F-actin and spectrin during platelet activation.
- Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
- Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
- Asymmetric cell divisions promote stratification and differentiation of mammalian skin.
- Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
- Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
- Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys.
- Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons.
- Differential actions of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: the role of Rho-GTPases.
- Distinct Epigenetic Effects of Tobacco Smoking in Whole Blood and among Leukocyte Subtypes.
- Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial.
- Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
- G-protein-coupled receptors as signaling targets for antiplatelet therapy.
- Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
- Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase. Functional specificity among G-protein coupled receptor kinases.
- PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
- Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations.
- Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
- Protease-activated receptor-2 signaling triggers dendritic cell development.
- Receptor and G betagamma isoform-specific interactions with G protein-coupled receptor kinases.
- Reduced reperfusion-induced Ins(1,4,5)P3 generation and arrhythmias in hearts expressing constitutively active alpha1B-adrenergic receptors.
- Response of blood leukocytes to thrombin receptor peptides.
- Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
- The role of platelet receptors and adhesion molecules in coronary artery disease.
- Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.
- Thrombin receptor. Variations on a theme.
- Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages.
- Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
- Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
- Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
- Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
- beta -Arrestins regulate protease-activated receptor-1 desensitization but not internalization or Down-regulation.